Human high-density lipoprotein particles prevent activation of the JNK pathway induced by human oxidised low-density lipoprotein particles in pancreatic beta cells
- First Online:
- Cite this article as:
- Abderrahmani, A., Niederhauser, G., Favre, D. et al. Diabetologia (2007) 50: 1304. doi:10.1007/s00125-007-0642-z
We explored the potential adverse effects of pro-atherogenic oxidised LDL-cholesterol particles on beta cell function.
Materials and methods
Isolated human and rat islets and different insulin-secreting cell lines were incubated with human oxidised LDL with or without HDL particles. The insulin level was monitored by ELISA, real-time PCR and a rat insulin promoter construct linked to luciferase gene reporter. Cell apoptosis was determined by scoring cells displaying pycnotic nuclei.
Prolonged incubation with human oxidised LDL particles led to a reduction in preproinsulin expression levels, whereas the insulin level was preserved in the presence of native LDL-cholesterol. The loss of insulin production occurred at the transcriptional levels and was associated with an increase in activator protein-1 transcriptional activity. The rise in activator protein-1 activity resulted from activation of c-Jun N-terminal kinases (JNK, now known as mitogen-activated protein kinase 8 [MAPK8]) due to a subsequent decrease in islet-brain 1 (IB1; now known as MAPK8 interacting protein 1) levels. Consistent with the pro-apoptotic role of the JNK pathway, oxidised LDL also induced a twofold increase in the rate of beta cell apoptosis. Treatment of the cells with JNK inhibitor peptides or HDL countered the effects mediated by oxidised LDL.
These data provide strong evidence that oxidised LDL particles exert deleterious effects in the progression of beta cell failure in diabetes and that these effects can be countered by HDL particles.
KeywordsApoptosis Diabetes HDL Insulin JNK pathway MAPK Oxidised LDL Pancreatic beta cells
luciferase reporter construct driven by multimerised AP1 consensus sequences
B-cell leukaemia/lymphoma 2
islet brain 1
c-Jun N-terminal kinases
luciferase reporter construct
mitogen-activated protein kinase 8
rat insulin II promoter
rat insulin promoter element
rip linked to the luciferase reporter
A decline in the number of insulin-producing beta cells and/or their intrinsic ability to produce and/or secrete insulin contributes to the pathophysiology of type 2 diabetes . It is now accepted that this beta cell inadequacy results in part from oxidative stress due to adverse effects of chronic elevation of glucose and free or non-esterified fatty acids [2–4]. Among the major mechanisms that have been associated with oxidative stress, is induction of the c-Jun N-terminal kinases (JNK, now known as mitogen-activated protein kinase 8 [MAPK8]) signalling pathway, leading to activation of activator protein-1 (AP1) transcriptional factors complex [5, 6]. Suppression of this pathway prevents the loss of preproinsulin gene expression and apoptosis [7, 8].
Islet-brain 1/JNK-interacting protein 1 (IB1; now known as MAPK8 interacting protein 1) is a mammalian scaffold protein involved in the regulation of the JNK pathway [9–11]. One of the outcomes of this regulation is to prevent the activation of c-Jun (now known as JUN or Jun oncogene), a transcription factor included in the AP1 transcriptional complex that directly represses production of insulin and induces beta cell apoptosis [11–14]. Reduction in IB1 content diminishes preproinsulin mRNA levels and renders the cells more sensitive to stress-induced programmed death [11, 15, 16]. The importance of IB1 levels in beta cells has been confirmed in human diabetes. A missense mutation (S59N) in the gene encoding IB1 has been found to co-segregate with diabetes in a French family with a monogenic form of type 2 diabetes. Ex vivo, this mutation reduces the stability of IB1, leading to decreased insulin promoter activity and acceleration of the rate of cell apoptosis [11, 17].
Elevated levels of oxidised LDL-cholesterol, together with low HDL-cholesterol, are typical symptoms of diabetic dyslipidaemia and risk factors for prediabetic and diabetic patients to develop cardiovascular diseases [18–20]. Oxidised LDL is produced in the subendothelial space and is taken up by resident macrophages via scavenger receptors [21–23], leading to their transformation into foam cells. A recent report shows that beta cells express scavenger receptor class B, member 1 and CD36, two scavenger receptors for oxidised LDL, and that incubation of beta cells with oxidised LDL causes a decline in specialised tasks including insulin synthesis . Oxidised LDL can induce oxidative stress in several tissues, including activation of the JNK signalling pathway and AP1 transcriptional activity [25–27]. In view of these data, we postulated that JNK signalling is implicated in the alteration of insulin production and cell survival caused by oxidised LDL.
Herein, we provide evidence that oxidised LDL, but not native LDL, exerts deleterious effects on insulin levels and beta cell survival by activating the JNK pathway. Selective inhibition of this pathway with peptide inhibitors or incubation with human HDLs countered the effects mediated by oxidised LDL.
Materials and methods
Blood was collected from healthy donors. Plasma LDL fractions were isolated by sequential ultracentrifugation (LDL density, 1.063) and dialysed against PBS. Samples were analysed by SDS-PAGE to assess the integrity of apolipoproteins and the purity of the different fractions. The lipoprotein preparations contained less than 0.112 units of endotoxin/μmol cholesterol as determined by the kinetic chromogenic technique (Endotell, Allschwil, Switzerland). Oxidation of LDL particles (at 1 mg/ml protein concentration in PBS) was performed by incubation with 5 μmol/l CuSO4 at 37°C for 18 h. The oxidation reaction was stopped at 4°C for 30 min by adding 300 μmol/l EDTA and by thorough dialysis against PBS and subsequently against either DMEM or RPMI medium without fetal calf serum. The oxidation reaction was verified by determining the lipid peroxide content as previously described .
Preparation and culture of islets
Rat islets were isolated from the pancreas of male Sprague–Dawley rats weighing 250–350 g by ductal injection of collagenase. The purification of islets was conducted as described . Isolated human islets were obtained from the Cell Isolation and Transplantation Center (islets for research distribution programme) of the Geneva University Hospitals. Islets were cultured in CMRL-1066 supplemented with 10% fetal bovine serum (Mediatech, Herndon, VA, USA) in a 5% CO2 humidified atmosphere at 37°C.
Cell culture, transient transfection and plasmids
The insulin-secreting cell lines (MIN6 and INS-1E) and rat isolated islets were maintained as previously described . Transient transfection experiments were performed using a kit (Effectene Transfection Reagent kit; Qiagen, Basel, Switzerland) as reported . The following plasmids were used for the transfection assays: a 600-base pair sequence of the rat insulin II promoter (Rip) cloned upstream of the firefly luciferase gene ; rat insulin promoter element (RIPE)3Luc ; and a luciferase reporter construct (Luc) driven by multimerised AP1 consensus sequences (AP1Luc). The latter two are firefly luciferase reporter constructs corresponding to five copies of the (RIPE)3 binding site (containing the E elements) and to four copies of the canonical AP1-responsive elements inserted upstream of the TATA minimal promoter, respectively. Luciferase activities from the firefly and the renilla from the pRL-SV40 vector (Promega, Wallisellen, Switzerland) were measured using an assay system (Dual-Luciferase Reporter; Promega).
Measurement of insulin content
Cells (5 × 105) were plated in 24-well dishes and cultured in the presence of vehicle, native and oxidised LDL for 72 h. Afterwards, the cells were washed three times with a modified KRB/bicarbonate-HEPES buffer (140 mmol/l NaCl, 3.6 mmol/l KCl, 0.5 mmol/l NaH2PO4, 0.5 mmol/l MgSO4, 1.5 mmol/l CaCl2, 2 mmol/l NaHCO3, 10 mmol/l HEPES, 0.1% bovine serum albumin) containing 2 mmol/l glucose. Insulin contents were extracted with acid/ethanol solution and measured by ELISA (Linco Research, St Charles, MO, USA) as recommended by the manufacturer’s protocol.
Apoptosis was determined by scoring cells displaying pycnotic nuclei visualised with Hoechst 33342 (Invitrogen, Basel, Switzerland) .
Protein kinase assay
The preparation of whole-cell protein extracts and the kinase assays were conducted as previously described . Briefly, cell extracts were incubated for 1 h at room temperature with 1 μg glutathione S-transferase (GST)-Jun (amino acids 1–89) and 10 μl glutathione-agarose beads (Sigma-Aldrich, St-Gallen, Switzerland). After several washings, the beads were supplemented with JNK inhibitor or TAT (control) peptides for 20 min . The JNK inhibitor peptides used were the JNK binding domain of IB1, which was coupled covalently to an N-terminal ten-amino acid carrier peptide derived from the HIV-TAT48–57 sequence . The retro-inverso d-enantiomer TAT and JNK inhibitor peptides (Auspep PLT, Melbourne, VIC, Australia)  were a gift from C. Bonny (S. A. Xigen, Lausanne, Switzerland). Phosphorylation of substrate proteins was examined after overnight exposition of polyacrylamide gels to autoradiography; gel quantifications were accomplished by Phosphor-Imager analysis (Molecular Imager FX; Bio-Rad Laboratories, Basel, Switzerland).
Nuclear protein extracts preparation and electromobility shift assays
Nuclear protein extracts and binding reaction were conducted exactly as previously reported . The primers used as labelled probe were: AP1: sense: 5′-CGCTTGATGAGTCAGCCGGAA-3′ and antisense 5′-GGCTGACTCATCAAGCG-3′.
Western blotting, total RNA preparation and real-time PCR
For western blotting, the cell extracts were separated by SDS-PAGE and blotted on nitrocellulose membranes. The proteins were detected using specific antibodies and were visualised by chemiluminescence using horseradish peroxidase-coupled secondary antibodies. Total RNA from insulin-secreting cell lines and pancreatic islets was extracted using an RNA purification kit (Ambion, Austin, TX, USA) according to the manufacturer’s protocol. Reverse transcription reactions were performed as previously described . Real-time PCR assays were carried out on a real-time PCR detection system (MyiQ Single-Colour; Bio-Rad) using iQ SYBR Green Supermix (Bio-Rad), with 100 nmol/l primers, 1 μl of template per 20 μl of PCR and an annealing temperature of 59°C. Melting curve analyses were performed on all PCRs to rule out non-specific amplification. Reactions were carried out in triplicate. Primer sequences for PCR were as follows: mouse and human insulin, sense 5′-TGGCTTCTTCTACACACCCA-3′, antisense 5′-TCTAGTTGCAGTAGTTCTCCA-3′; mouse and human tubulin, sense 5′-GGAGGATGCTGCCAATAACT-3′, antisense 5′-GGTGGTGAGGATGGAATTGT-3′; rat and mouse Ib1, sense 5′-AGTGTCCAGCTTCCCTTGTC-3′, antisense 5′-TTACTGTGGCCCTCTCCTTG-3′; human IB1, sense 5′-ATCAGCCTGGAGGAGTTTGA-3′, antisense 5′-AGGTCCATCTGCAGCATCTC-3′; human FOS, sense 5′-TGATACACTCCAAGCGGAGAC-3′, antisense 5′-CCCAGTCTGCTGCATAGAAGG-3′; mouse ribosomal phosphoprotein P0 gene, sense 5′-ACCTCCTTCTTCCAGGCTTT-3′, antisense 5′-CCACCTTGTCTCCAGTCTTT-3′; mouse B-cell leukaemia/lymphoma 2 (Bcl2), sense: 5′-CTCCCGATTCATTGCAAGTT-3′, antisense 5′-TCTACTTCCTCCGCAATGCT-3′.
Data are expressed as means±SEM. Unpaired two-tailed Student’s t test was used to compare groups.
Oxidised LDL particles reduce insulin expression at the transcript level
Oxidised LDL diminishes the expression of insulin at the promoter level
Oxidised LDL induces JNK activity, increases AP1 transcriptional activity and downregulates expression of Ib1
Activation of the JNK pathway has often been associated with an increase in beta cell programmed death [8, 15, 40]. We therefore tested the viability of insulin-secreting cells in the presence of LDL-cholesterol preparations. As expected, the rate of apoptosis of the cells cultured with 2 mmol/l oxidised LDL-cholesterol for 72 h increased by threefold in MIN6 cells and rat isolated islets, whereas the viability of the cells incubated in the presence of native LDL was unchanged (Fig. 6b). The rate of apoptosis was similar when MIN6 cells were incubated either at 20 or at 10 mmol/l glucose. This result is in agreement with a previous report showing that glucose did not render cells more sensitive to the effects of LDL . Co-treatment with JNK inhibitors prevented the apoptosis of cells mediated by oxidised LDL (Fig. 6c). Real-time PCR experiments showed a reduction of Bcl2 expression (Fig. 6d). This result is in agreement with the induction of the apoptotic pathway by oxidised LDL as reported in endothelial cells . In contrast to early effects of oxidised LDL on insulin levels, the viability of the cells cultured with oxidised LDL for 48 h was apparently unchanged (data not shown). This result indicates that the loss of insulin expression induced by oxidised LDL probably precedes programmed cell death.
Taken together, our results indicate that the effects of oxidised LDL on insulin expression and beta cell survival are linked to activation of the JNK signalling pathway resulting from a decrease in IB1 contents.
HDL protects cells from oxidised LDL-induced loss of insulin expression and death
Several studies have reported expression of receptors for native and modified forms of LDL, including scavenger receptor class B, member 1 and CD36 scavenger receptors, as well as the uptake of these lipoproteins in pancreatic beta cells [24, 28, 33, 42]. Herein, in agreement with a previous study, we found that insulin-secreting cells cultured with oxidised LDL have reduced preproinsulin gene expression . This perturbed expression was observed at protein and mRNA levels, both in isolated human and rat islets and in several insulin-secreting cell lines. The reduced luciferase activity of RipLuc and the multimerised E elements-containing promoter (RIPE)3Luc suggests that oxidised LDL particles exert their action on the preproinsulin gene at the transcriptional levels. This effect is mediated through the E elements and is not the result of irreversible cell damage as can be seen from the fact that mutation of these elements prevents the changes in luciferase activity of (RIPE)3Luc triggered by oxidised LDL. Several lines of evidence support a role for c-Jun, a component of the AP1 transcriptional complex, in the decline of preproinsulin gene transcription mediated by oxidised LDL . Overexpression of c-Jun has been shown to indirectly repress the enhancer activity of the E elements by interfering with the transactivating capacity of basic helix loop helix transcription factors, which bind to the former element [13, 14]. Conversely, induction of insulin expression is accompanied by a decrease in c-Jun expression . In line with these observations, we found that the impaired preproinsulin expression is associated with an increase in AP1 transcriptional activity and c-Jun expression.
AP1 activity and c-Jun expression are induced by an unusually broad range of environmental stressors . Many of these stimuli activate JNKs, leading to enhanced AP1 transcriptional activity. In cultured human fibroblasts and human aortic endothelial cells, oxidised LDL has been reported to increase the activity of AP1 and JNK, respectively [25, 26, 45]. Moreover, activation of the JNK pathway by overexpressing mitogen activated protein kinase kinase kinase 1 in insulin-secreting cells reduces the luciferase activity of (RIPE)3Luc . For this reason, we presumed that activation of JNK by oxidised LDL was responsible for augmenting AP1 activity and therefore for reducing preproinsulin gene expression. Consistent with this, inhibition of JNK with JNK inhibitors prevented the loss of (RIPE)3Luc activity and the decrease in preproinsulin mRNA levels mediated by oxidised LDL. This finding furnishes new evidence for the possible involvement of the JNK pathway in impaired preproinsulin expression through the E element.
Increased JNK activity and c-Jun expression have been reported in many scenarios in which cells undergo apoptosis [46, 47]. As expected, oxidised LDL induced a rise in the rate of apoptosis and JNK inhibitors protected cells against this deleterious effect. The reduction of Bcl2 expression confirms activation of the apoptotic pathway induced by oxidised LDL. In contrast, native LDL at 2 mmol/l cholesterol concentration did not induce apoptosis. This result is in agreement with previous studies showing that native LDL-cholesterol at concentrations lower than 3.1 mmol/l cholesterol does not cause apoptosis [24, 28]. Some reports found no effects of oxidised LDL on apoptosis [24, 33]. The discrepancy between the latter studies and our data could be due to the length of exposure to oxidised LDL. Indeed, we observed that 48 h incubation with oxidised LDL is sufficient to initiate a slight decrease in insulin levels but not to affect the rate of apoptosis (data not shown). Thus, these data confirm that the loss of insulin levels caused by oxidised LDL is not a consequence of cell death and might precede the apoptotic events.
IB1 is a key modulator of the JNK pathway and is required for cell survival and insulin expression [11, 15]. Long-term exposure of cells to proapoptotic stimuli diminishes expression of Ib1 [15, 16]. Such a decrease induces the JNK pathway and the subsequent activation of AP1, thereby leading to impaired insulin synthesis and increased apoptosis [11, 15, 16]. As expected, IB1 levels were reduced in cells treated with oxidised LDL for 72 h. In contrast, these levels were unchanged after 45 min of treatment, although JNK activity occurred at that time point. Therefore, the data show that the early effects of oxidised LDL on induction of JNK activity do not require downregulation of IB1. However, the latter event can be responsible for maintaining prolonged activation of JNK.
In patients with diabetes and metabolic syndrome, low serum HDL levels and elevated oxidised LDL concentrations are risk factors for the the development of cardiovascular diseases [18–20]. While oxidised LDL has pro-atherogenic effects, HDL is known to be anti-atherogenic and cardioprotective. Besides its role in the reverse transport of cholesterol, HDL has been shown in vitro to exert its effects by inhibiting LDL oxidation and cell signalling mediated by oxidised LDL; it also counters several adverse biological effects, such as cytotoxicity and inflammatory responses triggered by oxidised LDL [19, 48, 49]. In this report, we establish that HDL efficiently counters the effects of oxidised LDL on apoptosis by restoring expression of Bcl2. One possible mechanism is the depletion by HDL of LDL from lipid peroxides through enzymatic hydrolysis of phospholipid hydroperoxides, a process effected by the HDL-bound enzyme paraoxonase. This has been shown to reduce cytokine production stimulated by oxidised LDL . In addition, the idea that HDL mediates its action by preventing activation of the JNK pathway is supported by the fact that JNK and AP1 activities were not induced and that IB1 and FOS levels were unaltered in cells co-cultured with oxidised LDL and HDL. This hypothesis is supported by the fact that HDL protects insulin-secreting cells from apoptosis induced by VLDL . As is the case here for oxidised LDL, VLDL-mediated apoptosis was linked to impaired Ib1 expression and an increase in JNK activity .
Our data also show that HDL exerted its effects on insulin levels and AP1 activity as early as the 48-h time point. At that incubation time, downregulation of Ib1 and apoptosis did not occur. Thus, HDL counters the oxidised LDL-mediated activation of JNK in a manner that is both dependent and independent of IB1. More than 20 proteins are associated with HDL. These include apolipoproteins that serve as structural components, cofactors or inhibitors of enzymes, as well as ligands of receptors. Future studies will have to clarify which of these components mediate the protective effects of HDL, which counter those of oxidised LDL, on beta cells.
Finally, this study highlights the biological consequences and the relationship between the levels of the modified lipoproteins and HDL for beta cell function. Reductions in the concentration of HDL could potentiate the effects of oxidised LDL, thereby contributing to beta cell dysfunction. Therefore, like hyperglycaemia and NEFA, modified LDL could contribute to the development of diabetes. A better understanding of the mechanisms underlying the effects of oxidised LDL and HDL will help elucidate the causes of human type 2 diabetes and may lead to novel strategies for treatment or prevention of diabetes.
This work was supported by grants from the Swiss National Foundation (3100A0-105425, 310000-109281/1, 3200B0-101746 and 3100A0-107819 to A. Abderrahmani, G. Waeber, R. Regazzi and C. Widmann, respectively). We were also supported by the Young Independent Investigator grant from the Swiss Society of Endocrinology and Diabetology to A. Abderrahmani, as well as by the Placide Nicod and Octav Botnar Foundations.
Duality of interest
The authors of this manuscript have no dualities of interest.